Baseline immunophenotyping
Parameter (absolute) . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Normal range . |
---|---|---|---|---|---|
CD3, cells/μL | 1593 | 694 | 1041 | 1285 | 650-2108 |
CD4/CD3, cells/μL | 513 | 289 | 637 | 460 | 358-1259 |
CD8/CD3, cells/μL | 1021 | 391 | 342 | 698 | 194-836 |
T4/T8 ratio | 0.50 | 0.74 | 1.87 | 0.66 | 0.74-3.58 |
CD20, cells/μL | 204 | 40 | 100 | 50 | 49-424 |
CD16+ or CD56+/CD3−, cells/μL | 481 | 227 | 549 | 535 | 87-505 |
IFNγR-α on CD14, % | 100 | 100 | 100 | 100 | 100 |
Parameter (absolute) . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Normal range . |
---|---|---|---|---|---|
CD3, cells/μL | 1593 | 694 | 1041 | 1285 | 650-2108 |
CD4/CD3, cells/μL | 513 | 289 | 637 | 460 | 358-1259 |
CD8/CD3, cells/μL | 1021 | 391 | 342 | 698 | 194-836 |
T4/T8 ratio | 0.50 | 0.74 | 1.87 | 0.66 | 0.74-3.58 |
CD20, cells/μL | 204 | 40 | 100 | 50 | 49-424 |
CD16+ or CD56+/CD3−, cells/μL | 481 | 227 | 549 | 535 | 87-505 |
IFNγR-α on CD14, % | 100 | 100 | 100 | 100 | 100 |